Provided by Tiger Trade Technology Pte. Ltd.

Sanofi SA

40.23
+0.03000.07%
Post-market: 40.350.1200+0.30%18:33 EDT
Volume:3.00M
Turnover:119.62M
Market Cap:96.39B
PE:21.58
High:40.27
Open:40.18
Low:39.58
Close:40.20
52wk High:52.68
52wk Low:39.18
Shares:2.40B
Float Shares:2.16B
Volume Ratio:0.75
T/O Rate:0.14%
Dividend:2.36
Dividend Rate:5.88%
EPS(TTM):1.86
EPS(LYR):3.76
ROE:5.71%
ROA:5.09%
PB:1.24
PE(LYR):10.70

Loading ...

Sanofi, Regeneron Seem Keen to Keep Working Together

Dow Jones
·
Aug 07

Sanofi Has Financial Muscle for Acquisitions

Dow Jones
·
Aug 07

Sanofi Submits New Application for Long-Acting RSV Antibody Treatment

Stock News
·
Aug 07

Sanofi Understands Its Problem, but Still Lacks Solutions

Dow Jones
·
Jul 31

Global Equities Roundup: Market Talk

Dow Jones
·
Jul 31

Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D

Benzinga Earnings
·
Jul 31

Sanofi SA Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

European Equities Traded in the US as American Depositary Receipts Track Sharply Higher in Thursday Trading

MT Newswires Live
·
Jul 30

Sanofi Shares Slide After CEO Signals Challenges to Fill Drug Pipeline

Dow Jones
·
Jul 30

Movement Alert|Sanofi SA Falls 6.38% in Regular Trading, New CEO Raises Guidance but Pipeline Gap Concerns Weigh on Shares

Market Focus
·
Jul 30

Stock Track | Sanofi Plummets 6.56% Intraday as Pipeline Cuts and R&D Uncertainty Overshadow Upgraded Guidance

Stock Track
·
Jul 30

Stock Track | Sanofi Tumbles 5.13% in Pre-Market as Pipeline Cuts and R&D Uncertainty Overshadow Upgraded Guidance

Stock Track
·
Jul 30

Regeneron Posts Higher 2Q Revenue, Sees Improving Profit

Dow Jones
·
Jul 30

Movement Alert|Sanofi SA Falls 3.08% in Pre-Market Trading, New CEO Raises Guidance but Pipeline Gaps Weigh on Sentiment

Market Focus
·
Jul 30

New CEO Upgrades Guidance Yet Shares Fall as Sanofi's Pipeline Drought Becomes a Key Weakness

Stock News
·
Jul 30

Sanofi's New CEO Might be Done with Major Portfolio Pruning

Dow Jones
·
Jul 30

Sanofi Might be Better Off Favoring Deals over Internal Drugs

Dow Jones
·
Jul 30

Sanofi Targets Dual RSV–HMPV Opportunity With Fresh Phase 1/2 Vaccine Study

TIPRANKS
·
Jul 30

Sanofi Pauses Key Bronchiectasis Trial, Raising Questions For SNY Investors

TIPRANKS
·
Jul 30

Movement Alert|Sanofi SA Rises 3.07% in Regular Trading, Pharma Sector Rallies Ahead of Q2 Earnings

Market Focus
·
Jul 28